



CDN-20011/105/2026-COORDINATION-NMC
Government of India
National Medical Commission
(Policy & Coordination Division)



Pocket - 14, Sector - 8,
Dwarka Phase - 1, New Delhi - 110 077.

Dated: 25th March, 2026.

ADVISORY

Subject : Compliance with Hon'ble Supreme Court Judgement dated 30.01.2026.

A D. O. letter no. M - 11019 / 5 / 2026 - CG dated the 10th March, 2026 with respect to Judgement (D. No. 14452 / 2022 / SEC-X dated 3rd February, 2026) of the Hon'ble Supreme Court of India in the matter of *Yash Charitable Trust & Ors. versus Union of India & Ors.* (W.P. (C) No. 369 of 2022) concerning issues related to the use of stem cell therapy for the treatment of Autism Spectrum Disorder (ASD) is attached herewith.

2. All Medical Colleges / Institutions are requested to ensure compliance with the directions of the Hon'ble Supreme of India.

(Dr. Raghav Langer)
Secretary, National Medical Commission

Enclosure : D. O. letter no. M - 11019 / 5 / 2026 - CG dated the 10th March 2026 alongwith Annexure.

To,
Dean / Principal all the Medical Colleges / Institutions

Digitally signed by
Dr.Raghav Langer
Date: 25-03-2026
12:27:42



डॉ. राजीव बहल, एमडी, पीएचडी.
DR. RAJIV BAHL MD, PhD



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH

सचिव, भारत सरकार
स्वास्थ्य अनुसंधान विभाग
स्वास्थ्य एवं परिवार कल्याण मंत्रालय एवं
महानिदेशक
भारतीय आयुर्विज्ञान अनुसंधान परिषद
Secretary, Government of India
Department of Health Research
Ministry of Health & Family Welfare
Director-General
Indian Council of Medical Research

D.O No. M-11019/5/2026-CG

Date: 10th March, 2026

Subject: Compliance with Hon'ble Supreme Court Judgment dated 30th January 2026

Dear Dr. Sheth,

This has reference to the judgment (D. No. 14452/2022/SEC-X dated 3rd February 2026) of Hon'ble Supreme Court of India in the matter of *Yash Charitable Trust & Ors. versus Union of India & Ors.* (W.P. (C) No. 369 of 2022), concerning issues related to the use of stem cell therapy for the treatment of Autism Spectrum Disorder (ASD). This judgement has important implications for giving stem cell therapy in India. The following is being conveyed to ensure compliance with the directions of the Hon'ble Court.

2. Stem cell therapies in routine practice shall be permitted only for disease conditions specified in the list of MoHFW approved indications as Standard Care (enclosed herewith).
3. Other than the approved indications, Stem cell therapy is permissible only in the context of research. If stem cells have undergone more than minimal manipulation, the research will be regulated by CDSCO. If stem cells have undergone less than minimal manipulation, research will be regulated by DHR, and in this case, in addition to the recommendations of the Institutional Ethics Committee (IEC) registered with DHR, the trials will have to be approved by the National Stem Cell Research Regulation Committee. The levels of manipulation for stem cell therapy have been defined by CDSCO.
4. Stem cell research shall be permissible only as part of an approved clinical trial. This research will be required to comply with all ICMR ethical guidelines including written informed consent, no cost to the patient and provision of compensation in case of injury or death.
5. Any stem cell treatment not included in the list of standard care indications, or not approved by CDSCO or DHR shall be deemed illegal and liable to action in accordance with

law. It is reiterated that biomedical research can only be approved by IEC registered with DHR.

6. You are requested to issue an advisory stating that **firstly, Routine practice should be restricted ONLY to the approved indications listed in ICMR/DHR/MoHFW guidelines. Secondly, beyond the approved list of disease conditions, Stem cell research needs to be conducted in compliance with ICMR Ethical Guidelines and with prior approval of either CDSCO or DHR depending on the level of manipulation of stem cells.**

7. This advisory may be circulated to all registered medical practitioners, medical colleges, and affiliated institutions under the jurisdiction of the Commission to ensure strict compliance. Any deviation from the above shall be liable to regulatory and legal action in accordance with law.

With warm regards,

With warm regards,

Yours Sincerely,

Rajiv Bahl
(Rajiv Bahl)

Dr Abhijat Chandrakant Sheth
Chairman, National Medical Commission
Pocket- 14, Sector - 8
Dwarka Phase -1, New Delhi - 110077

LIST OF MOHFW APPROVED DISEASE CONDITIONS FOR STEM CELL THERAPY
AS STANDARD CARE

Only safe and appropriately performed hematopoietic stem cell transplantation is recommended as Standard of Care for the following indications**. Mesenchymal stem cell transplantation is not recommended for any disease condition.

Adults:

1. Acute Myeloid Leukemia
2. Acute lymphoblastic leukemia
3. Chronic Myeloid Leukemia
4. Myelofibrosis
5. Myelodysplastic syndromes
6. Chronic lymphocytic leukemia
7. Diffuse Large b cell lymphoma
8. Follicular lymphoma
9. Mantle cell lymphoma
10. Peripheral T cell lymphoma
11. Hodgkin's Lymphoma
12. Multiple Myeloma
13. Acquired Severe Aplastic Anemia
14. Constitutional Severe Aplastic Anemia
15. Aplastic Anemia/Paroxysmal hemoglobinuria
16. Germ Cell tumors
17. Multiple Sclerosis
18. Systemic Sclerosis

Pediatrics:

1. Acute Myeloid Leukemia
2. Acute lymphoblastic leukemia
3. Chronic Myeloid Leukemia
4. Myelodysplastic syndromes/ Juvenile myelomonocytic leukemia
5. Non-Hodgkin Lymphoma
6. Hodgkin lymphoma
7. Primary immunodeficiency diseases
8. Mucopolysaccharidoses
9. Thalassemia/ SCD
10. Osteopetrosis
11. Acquired Severe Aplastic Anemia
12. Inherited Bone Marrow failure syndromes
13. Ewings Sarcoma
14. Neuroblastoma

**For details, refer to Hematopoietic Cell Transplantation Guidelines 2021 (Annexure I-Standard of Care only)